Research & Development
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designati...
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
17 March 2026 - US biopharmaceutical company Sentynl Therapeutics Inc, a wholly-owned subsidiary of Zydus Lifesciences Limited, announced on Monday that it has signed an agreement with PRG S&T, a ...
CMIC agrees agentic AI partnership with Bluenote
11 March 2026 - CMIC Co Ltd, a contract research organisation (CRO) jointly owned by US investment firm Blackstone and Japan-based CMIC HOLDINGS Co Ltd, announced on Tuesday that it has partnered with...
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
...
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD
9 March 2026 - Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-D...
AstraZeneca and Daiichi Sankyo's Enhertu receives US priority review for post-neoadjuvant HER2-positive early breast cancer
9 March 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the ...